Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial

Abd-Elsalam et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.21-0606, NCT04345419
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
This paper was retracted.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
Abd-Elsalam et al., 10 Sep 2021, Egypt, peer-reviewed, 15 authors, trial NCT04345419 (history). Contact: sherif.abdelbaky@med.tanta.edu.eg.
This PaperRemdesivirAll
Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
Sherief Abd-Elsalam, Ossama Ashraf Ahmed, Noha O Mansour, Doaa H Abdelaziz, Marwa Salama, Mohamed Hassan Ahmed Fouad, Shaimaa Soliman, Ahmed Mohamed Naguib, Mohamed Sayed Hantera, Ibrahim S Ibrahim, Mohamed Torky, Hany M Dabbous, Mohamed Samir Abd El Ghafar, Enas A Abdul-Baki, Mohammed Elhendawy
The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.21-0606
To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30-60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P , 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P 5 0.469). The mortality rate was comparable between the two groups (P 5 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P 5 0.039, 0.003, 0.001, and , 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low-and middle-income countries when other effective options are scarce.
R E T R A C T E D
References
Bansal, Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis, Front Med
Beigel, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Beigel, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Dabbous, Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Arch Virol
Goldman, Remdesivir for 5 or 10 days in patients with severe COVID-19, N Engl J Med
Gordon, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J Biol Chem
Horby, Dexamethasone in hospitalized patients with covid-19, N Engl J Med
Hsu, Lai, Yen, Chen, Chen, Efficacy ofremdesivir inCOVID-19patientswithasimulatedtwo-arm controlled study, medRxiv, doi:10.1101/2020.05.02.20088559
Kalil, Baricitinib plus remdesivir for hospitalized adults with COVID-19, N Engl J Med
Olender, Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care, Clin Infect Dis, doi:10.1093/cid/ciaa1041
Pizzorno, Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia, Cell Reports Med
Rees, COVID-19 length of hospital stay: a systematic review and data synthesis, BMC Med, doi:10.1186/s12916-020-01726-3
Rezagholizadeh, Khiali, Sarbakhsh, Entezari-Maleki, Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis, Eur J Pharmacol
Sharifpour, Rangaraju, Liu, C-reactive protein as a prognostic indicator in hospitalized patients with COVID-19, PLoS One
Sheahan, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med, doi:10.1126/scitranslmed.aal3653
Soni, Gopalakrishnan, Vaishya, Prabu, D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases, Diabetes Metab Syndr
Spinner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Twreafc, Tw, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
Uzunova, Filipova, Pavlova, Vekov, Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2, Biomed Pharmacother, doi:10.1016/j.biopha.2020.110668
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wang, Wang, Wang, Lau, Zhang et al., COVID-19 in early 2021: current status and looking forward, Signal Transduct Target Ther
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit